Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Antisense and TJAB Advance MS Drug

publication date: Mar 19, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Antisense Therapeutics, an Australian biopharma, has contracted with Pharmaron to conduct a toxicology study of ATL1102, a multiple sclerosis drug. The company hopes to stage a China Phase IIb trial of the drug in China in partnership with Tianjin International Joint Academy of Biotechnology and Medicine (TJAB). The two entities extended the deadline for establishing a JV to develop ATL1102 until September 30, 2013, More details....

Stock Symbol: (ASX: ANP)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors